Enache Dana Elena, Georgescu Claudia Valentina, Pătrană Nicoleta
Department of Pathology, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Rom J Morphol Embryol. 2012;53(3 Suppl):755-62.
This study involved 40 ER-negative female patients with invasive breast cancer, aged between 25 and 88 years, diagnosed at Emergency County Hospital of Craiova, Romania, during a two-year interval (2010-2011). All patients that took part in the study were subjected to a preoperative mammography exam, and later to HP and IHC exams, in order to detect the ER, PR and HER2 status. These exams were followed by CISH in ambiguous HER2 cases. The tumor detection method was palpation in 16 cases, whereas in 24 cases the method used was the screening mammography. Histopathologically, the analyzed tumors were infiltrative ductal carcinoma (35 cases), lobular carcinoma (one case), mucinous (two cases) and metaplastic carcinoma (two cases). Depending on the status of the oncoprotein HER2, the 40 ER-negative female patients included in the study formed two groups: the ER-negative, HER2-positive (11 cases, 27.5%) formed the first group and the ER-negative, HER2-negative (29 cases, 72.5%) formed the second group. Depending on the expression of the receptors for progesterone, 60% of cases were classified as triple negative mammary carcinomas (ER-, PR-, HER2-). The comparative study of the ER-negative, HER2-positive and the ER-negative, HER2-negative mammary carcinomas showed that the tumors of the ER-negative, HER2-positive group were mostly high degree cancers (80% vs. 56%), with negative progesterone receptors (81.81% vs. 48.27%), associated with axillary lymph node metastasis (63.63% vs. 48.27%), and were detected at a higher cancer stage (II/III) (81.81% vs. 62.06%). Regarding the mammographic features, the ER-negative HER2-positive breast cancers are more likely to be irregular masses (62.5% vs. 33.33%), with spiculated margins (45.45% vs. 6.9%), frequently associated with dense or heterogeneously dense breast (82% vs. 69%) and pleomorphic calcifications (62.5% vs. 28.57%) comparative with ER-negative HER2-negative cancers that were more frequently round/oval mass, with indistinct margins and a great variety of morphological types of calcifications. The correlations between imaging and clinical aspects, together with the biomarker expression in breast cancers may sooner suggest the biological characteristics of these tumors, thus hinting at their evolution and helping to identify female patients with invasive breast cancer that will positively respond to an aimed therapy.
本研究纳入了40例雌激素受体(ER)阴性的浸润性乳腺癌女性患者,年龄在25至88岁之间,于罗马尼亚克拉约瓦县急诊医院在两年期间(2010 - 2011年)确诊。所有参与研究的患者均接受了术前乳腺钼靶检查,随后进行了苏木精-伊红(HE)染色和免疫组化(IHC)检查,以检测ER、孕激素受体(PR)和人表皮生长因子受体2(HER2)的状态。对于HER2情况不明确的病例,随后进行了原位杂交(CISH)检查。肿瘤检测方法在16例中为触诊,而在24例中使用的方法是乳腺钼靶筛查。组织病理学上,分析的肿瘤为浸润性导管癌(35例)、小叶癌(1例)、黏液癌(2例)和化生性癌(2例)。根据癌蛋白HER2的状态,本研究纳入的40例ER阴性女性患者分为两组:ER阴性、HER2阳性(11例,27.5%)为第一组,ER阴性、HER2阴性(29例,72.5%)为第二组。根据孕激素受体的表达情况,60%的病例被归类为三阴性乳腺癌(ER-、PR-、HER2-)。对ER阴性、HER2阳性和ER阴性、HER2阴性乳腺癌的比较研究表明,ER阴性、HER2阳性组的肿瘤大多为高分化癌(80%对56%),孕激素受体阴性(81.81%对48.27%),伴有腋窝淋巴结转移(63.63%对48.27%),且在较高癌症分期(II/III期)被检测到(81.81%对62.06%)。关于乳腺钼靶特征,与ER阴性、HER2阴性乳腺癌相比,ER阴性、HER2阳性乳腺癌更可能为不规则肿块(62.5%对33.33%),边缘有毛刺(45.45%对6.9%),常伴有致密或不均匀致密乳腺(82%对69%)和多形性钙化(62.5%对28.57%),而ER阴性、HER2阴性乳腺癌更常见圆形/椭圆形肿块,边缘不清,且钙化的形态类型多样。乳腺癌成像与临床特征之间的相关性以及生物标志物表达情况可能更早地提示这些肿瘤的生物学特性,从而暗示其发展情况,并有助于识别对靶向治疗有积极反应的浸润性乳腺癌女性患者。